A severe adverse event experienced by a participant in AstraZeneca's clinical trial of a COVID-19 vaccine developed at the University of Oxford is a setback, but even if the first round of vaccines making it to human tests fail, many other candidates await. One that has yet to gain traction -- developed by virologist Peter Palese of Icahn School of Medicine -- consists of an avian virus genetically modified to make a SARS-CoV-2 surface protein, and it protected mice from a model of COVID-19.
Numerous COVID-19 vaccines going through animal testing
Sign up for FBR SmartBrief
Biomedical Research News
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.